缺血性卒中免疫调节治疗的研究进展

doi:10.3969/j.issn.1673-5765.2020.01.009

摘要/Abstract

摘要：

在缺血性卒中的病理过程中，免疫系统通过固有免疫反应和适应性免疫反应发挥着重要的作用。缺血性卒中发生后，一方面通过激活的免疫细胞释放破坏性细胞因子，损伤血管内皮，破坏血脑屏障和神经元，并在淋巴细胞与特异性抗原结合后诱发适应性免疫反应，加重神经元损伤；另一方面通过清除坏死组织，释放保护性细胞因子，调节免疫抑制等途径减轻神经元损伤。免疫调节治疗为卒中的治疗提供了一个新的方向，以芬戈莫德、米诺环素、那他珠单抗等药物为代表的免疫调节药物在缺血性卒中动物模型实验和临床研究中都呈现出较好的疗效。本文就缺血性卒中免疫调节治疗的研究进展做一综述。

文章导读： 缺血性卒中后的免疫反应复杂，免疫调节治疗提供了新的治疗手段，但仍需要深入研究。

关键词: 卒中; 治疗; 免疫调节

Abstract:

The immune system plays an important role in the pathological process of ischemic stroke through innate and adaptive immune responses. After ischemic stroke onset, destructive cytokines released by activated immune cells can damage vascular endothelium, blood-brain barrier and neurons. Then adaptive immune response is activated by the combination of lymphocytes and specific antigen and aggravates neuron injury. On the other hand, there are protective responses in the body, neuron injury can be alleviated by removing necrotic tissue, releasing protective cytokines and regulating immunosuppression. Immunomodulation therapy provides a new direction for the treatment of stroke. Immunoregulatory drugs such as fingomod, minocycline and natazumab have shown good efficacy in animal model experiments and clinical studies of ischemic stroke. This article reviews the research progress of immunomodulation therapy for ischemic stroke.

Key words: Stroke; Therapy; Immunomodulation

邹明. 缺血性卒中免疫调节治疗的研究进展[J]. 中国卒中杂志, 2020, 15(01): 57-62.

ZOU Ming. Progress of Immunomodulation Therapy for Ischemic Stroke[J]. Chinese Journal of Stroke, 2020, 15(01): 57-62.

参考文献

[1] YANG G，WANG Y，ZENG Y，et al. Rapid health

transition in China，1990-2010：findings from the

Global Burden of Disease Study 2010[J]. Lancet，

2013，381（9882）：1987-2015.

[2] ZHOU M，WANG H，ZENG X，et al. Mortality，

morbidity，and risk factors in China and its provinces，

1990-2017：a systematic analysis for the Global

Burden of Disease Study 2017[J]. Lancet，2019，394

（10204）：1145-1158.

[3] WU S，WU B，LIU M，et al. Stroke in China：

advances and challenges in epidemiology，prevention，

and management[J]. Lancet Neurol，2019，18（4）：

394-405.

[4] 《中国脑卒中防治报告2018》编写组. 我国脑卒中防

治仍面临巨大挑战——《中国脑卒中防治报告2018》

概要[J]. 中国循环杂志，2019，34（2）：105-119.

[5] POWERS W J，RABINSTEIN A A，ACKERSON

T，et al. 2018 guidelines for the early management

of patients with acute ischemic stroke：a guideline

for healthcare professionals from the American

Heart Association/American Stroke Association[J/

OL]. Stroke，2018，49（3）：e46-e99. https：//doi.

org/10.1161/STR.0000000000000158.[6] CHAMORRO Á，MEISEL A，PLANAS A M，et al.

The immunology of acute stroke[J]. Nat Rev Neurol，

2012，8（7）：401-410.

[7] SHI K，TIAN D C，LI Z G，et al. Global brain

inflammation in stroke[J]. Lancet Neurol，2019，18

（11）：1058-1066.

[8] KURZEPA J，KURZEPA J，GOLAB P，et al. The

significance of matrix metalloproteinase（MMP）-2

and MMP-9 in the ischemic stroke[J]. Int J Neurosci，

2014，124（10）：707-716.

[9] MARSH B J，WILLIAMS-KARNESKY R L，

STENZEL-POORE M P. Toll-like receptor signaling

in endogenous neuroprotection and stroke[J].

Neuroscience，2009，158（3）：1007-1020.

[10] IADECOLA C，ANRATHER J. The immunology of

stroke：from mechanisms to translation[J]. Nat Med，

2011，17（7）：796-808.

[11] YILMAZ G，ARUMUGAM T V，STOKES K Y，et

al. Role of T lymphocytes and interferon-gamma

in ischemic stroke[J]. Circulation，2006，113（17）：

2105-2112.

[12] PLANAS A M，GÓMEZ-CHOCO M，URRA X，

et al. Brain-derived antigens in lymphoid tissue of

patients with acute stroke[J]. J Immunol，2012，188

（5）：2156-2163.

[13] KAMEL H，IADECOLA C. Brain-immune

interactions and ischemic stroke：clinical

implications[J]. Arch Neurol，2012，69（5）：576-581.

[14] ZIV Y，RON N，BUTOVSKY O，et al. Immune

cells contribute to the maintenance of neurogenesis

and spatial learning abilities in adulthood[J]. Nat

Neurosci，2006，9（2）：268-275.

[15] HUG A，DALPKE A，WIECZOREK N，et al.

Infarct volume is a major determiner of poststroke

immune cell function and susceptibility to

infection[J]. Stroke，2009，40（10）：3226-3232.

[16] MEISEL C，SCHWAB J M，PRASS K，et al.

Central nervous system injury-induced immune

deficiency syndrome[J]. Nat Rev Neurosci，2005，6

（10）：775-786.

[17] EMSLEY H C，HOPKINS S J. Post-stroke

immunodepression and infection：an emerging

concept[J]. Infect Disord Drug Targets，2010，10（2）：

91-97.

[18] SHIM R，WONG C H. Ischemia，

Immunosuppression and infection--tackling the

predicaments of post-stroke complications[J/

OL]. Int J Mol Sci，2016，17（1）：E64. https：//doi.

org/10.3390/ijms17010064.

[19] LIESZ A，ZHOU W，MRACSKÓ É，et al. Inhibition

of lymphocyte trafficking shields the brain against

deleterious neuroinflammation after stroke[J]. Brain，

2011，134（Pt 3）：704-720.

[20] KONOEDA F，SHICHITA T，YOSHIDA H，et al.

Therapeutic effect of IL-12/23 and their signaling

pathway blockade on brain ischemia model[J].

Biochem Biophys Res Commun，2010，402（3）：

500-506.

[21] URRA X，VILLAMOR N，AMARO S，et al.

Monocyte subtypes predict clinical course and

prognosis in human stroke[J]. J Cereb Blood Flow

Metab，2009，29（5）：994-1002.

[22] PHAM T H，OKADA T，MATLOUBIAN M，et al.

S1P1 receptor signaling overrides retention mediated

by G alpha i-coupled receptors to promote T cell

egress[J]. Immunity，2008，28（1）：122-133.

[23] WEI Y，YEMISCI M，KIM H H，et al. Fingolimod

provides long-term protection in rodent models of

cerebral ischemia[J]. Ann Neurol，2011，69（1）：

119-129.

[24] TISATO V，SECCHIERO P，RIMONDI E，et

al. GM-CSF exhibits anti-inflammatory activity

on endothelial cells derived from chronic venous

disease patients[J/OL]. Mediators Inflamm，2013，

2013：561689. https：//doi.org/10.1155/2013/561689.

[25] SALAS-PERDOMO A，MIRÓ-MUR F，

GALLIZIOLI M，et al. Role of the S1P pathway and

inhibition by fingolimod in preventing hemorrhagic

transformation after stroke[J]. Sci Rep，2019，9（1）：

8309.

[26] HASEGAWA Y，SUZUKI H，SOZEN T，et al.

Activation of sphingosine 1-phosphate receptor-1 by

FTY720 is neuroprotective after ischemic stroke in

rats[J]. Stroke，2010，41（2）：368-374.

[27] LIU J，ZHANG C，TAO W，et al. Systematic review

and meta-analysis of the efficacy of sphingosine-

1-phosphate（S1P）receptor agonist FTY720

（fingolimod）in animal models of stroke[J]. Int J

Neurosci，2013，123（3）：163-169.

[28] FU Y，ZHANG N，REN L，et al. Impact of an

immune modulator fingolimod on acute ischemic

stroke[J]. Proc Natl Acad Sci USA，2014，111（51）：

18315-18320.

[29] ZHU Z，FU Y，TIAN D，et al. Combination of the

immune modulator fingolimod with alteplase in

acute ischemic stroke：a pilot trial[J]. Circulation，

2015，132（12）：1104-1112.

[30] TIAN D C，SHI K，ZHU Z，et al. Fingolimod

enhances the efficacy of delayed alteplase

administration in acute ischemic stroke by promoting

anterograde reperfusion and retrograde collateral

flow[J]. Ann Neurol，2018，84（5）：717-728.[31] ZHANG S，ZHOU Y，ZHANG R，et al. Rationale

and design of combination of an immune modulator

Fingolimod with Alteplase bridging with Mechanical

Thrombectomy in Acute Ischemic Stroke（FAMTAIS）

trial[J]. Int J Stroke，2017，12（8）：906-909.

[32] YENARI M A，XU L，TANG X N，et al. Microglia

potentiate damage to blood-brain barrier constituents：

improvement by minocycline in vivo and in vitro[J].

Stroke，2006，37（4）：1087-1093.

[33] YANG Y，SALAYANDIA V M，THOMPSON

J F，et al. Attenuation of acute stroke injury in

rat brain by minocycline promotes blood-brain

barrier remodeling and alternative microglia/

macrophage activation during recovery[J/OL]. J

Neuroinflammation，2015，12：26. https：//doi.

org/10.1186/s12974-015-0245-4.

[34] MURATA Y，ROSELL A，SCANNEVIN R H，et

al. Extension of the thrombolytic time window with

minocycline in experimental stroke[J]. Stroke，2008，

39（12）：3372-3377.

[35] LU Y，XIAO G，LUO W. Minocycline suppresses

NLRP3 inflammasome activation in experimental

ischemic stroke[J]. Neuroimmunomodulation，2016，

23（4）：230-238.

[36] PARK C H，SHIN T K，LEE H Y，et al.

Matrix metalloproteinase inhibitors attenuate

neuroinflammation following focal cerebral ischemia

in mice[J]. Korean J Physiol Pharmacol，2011，15（2）：

115-122.

[37] LAMPL Y，BOAZ M，GILAD R，et al. Minocycline

treatment in acute stroke：an open-label，evaluatorblinded

study[J]. Neurology，2007，69（14）：1404-

1410.

[38] PADMA SRIVASTAVA M V，BHASIN A，BHATIA

R，et al. Efficacy of minocycline in acute ischemic

stroke：a single-blinded，placebo-controlled trial[J].

Neurol India，2012，60（1）：23-28.

[39] KOHLER E，PRENTICE D A，BATES T R，et

al. Intravenous minocycline in acute stroke：a

randomized，controlled pilot study and metaanalysis[

J]. Stroke，2013，44（9）：2493-2499.

[40] MALHOTRA K，CHANG J J，KHUNGER A，et al.

Minocycline for acute stroke treatment：a systematic

review and meta-analysis of randomized clinical

trials[J]. J Neurol，2018，265（6884）：1871-1879.

[41] BECKER K，KINDRICK D，RELTON J，et al.

Antibody to the alpha4 integrin decreases infarct

size in transient focal cerebral ischemia in rats[J].

Stroke，2001，32（1）：206-211.

[42] NEUMANN J，RIEK-BURCHARDT M，HERZ J，

et al. Very-late-antigen-4（VLA-4）-mediated brain

invasion by neutrophils leads to interactions with

microglia，increased ischemic injury and impaired

behavior in experimental stroke[J]. Acta Neuropathol，

2015，129（2）：259-277.

[43] LANGHAUSER F，KRAFT P，GÖB E，et al.

Blocking of α4 integrin does not protect from acute

ischemic stroke in mice[J]. Stroke，2014，45（6）：

1799-1806.

[44] ELKINS J，VELTKAMP R，MONTANER J，et al.

Safety and efficacy of natalizumab in patients with

acute ischaemic stroke（ACTION）：a randomised，

placebo-controlled，double-blind phase 2 trial[J].

Lancet Neurol，2017，16（3）：217-226.

[45] RELTON J K，ROTHWELL N J. Interleukin-1

receptor antagonist inhibits ischaemic and

excitotoxic neuronal damage in the rat[J]. Brain Res

Bull，1992，29（2）：243-246.

[46] BANWELL V，SENA E S，MACLEOD M R.

Systematic review and stratified meta-analysis of

the efficacy of interleukin-1 receptor antagonist in

animal models of stroke[J]. J Stroke Cerebrovasc Dis，

2009，18（4）：269-276.

[47] EMSLEY H C，SMITH C J，GEORGIOU R F，et

al. A randomised phase II study of interleukin-1

receptor antagonist in acute stroke patients[J]. J

Neurol Neurosurg Psychiatry，2005，76（1）：1366-

1372.

[48] SMITH C J，HULME S，VAIL A，et al. SCILSTROKE（

Subcutaneous Interleukin-1 Receptor

Antagonist in Ischemic Stroke）：a randomized

controlled phase 2 trial[J]. Stroke，2018，49（5）：

1210-1216.